FRA:5EA • US28414H1032
The current stock price of 5EA.DE is 21.715 EUR. In the past month the price increased by 14.92%.
ChartMill assigns a technical rating of 4 / 10 to 5EA.DE.
ChartMill assigns a fundamental rating of 2 / 10 to 5EA.DE. 5EA.DE may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months 5EA.DE reported a non-GAAP Earnings per Share(EPS) of 0.81. The EPS increased by 12.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.78% | ||
| ROA | 0.27% | ||
| ROE | 0.53% | ||
| Debt/Equity | 0.59 |
22 analysts have analysed 5EA.DE and the average price target is 22.15 EUR. This implies a price increase of 1.99% is expected in the next year compared to the current price of 21.715.
For the next year, analysts expect an EPS growth of 5.08% and a revenue growth 5.5% for 5EA.DE
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1SAN | SANOFI | 9.21 | 199.188B | ||
| SNW | SANOFI | 9.22 | 191.629B | ||
| SAN | SANOFI | 9.18 | 191.049B | ||
| MRK | MERCK KGAA | 14.87 | 54.521B | ||
| UCB | UCB SA | 27.18 | 53.237B | ||
| 1MRK | MERCK KGAA | 14.2 | 53.065B | ||
| UNC | UCB SA | 26.19 | 52.381B | ||
| 1BAYN | BAYER AG-REG | 9.41 | 45.191B | ||
| BAYN | BAYER AG-REG | 9.41 | 44.887B | ||
| IPN | IPSEN | 13.56 | 12.37B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
ELANCO ANIMAL HEALTH INC
450 Elanco Circle
Indianapolis INDIANA US
Employees: 9225
Phone: 18773526261
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. The company is headquartered in Indianapolis, Indiana and currently employs 9,000 full-time employees. The company went IPO on 2018-09-20. The firm's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). The company has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The firm's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
The current stock price of 5EA.DE is 21.715 EUR. The price increased by 4.22% in the last trading session.
5EA.DE does not pay a dividend.
5EA.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
ELANCO ANIMAL HEALTH INC (5EA.DE) currently has 9225 employees.
You can find the ownership structure of ELANCO ANIMAL HEALTH INC (5EA.DE) on the Ownership tab.